9 completed, 1 recruiting, 1 terminated. 7 Phase 1, 3 Phase 2, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 7 |
| Phase 2 | 3 | Completed 1, Recruiting 1, Terminated 1 |
| Early Phase 1 | 1 | Completed 1 |
Follow Akesobio Australia Pty Ltd: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorectal Cancer Ivonescimab - Metastatic Colorectal Cancer | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 90 | 2025-07-28 | 2026-05-20 |
| A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK127 in Combination With AK104 in Advanced and Metastatic Solid Tumours AK127, AK104 - Advanced or Metastatic Solid Tumours | Early Phase 1 | Completed | Akesobio Australia Pty Ltd | 67 | 2021-10-12 | 2025-12-04 |
| Phase 2 Study of Efficacy and Safety of AK120, in Subjects With Moderate-to-Severe Atopic Dermatitis Placebo, AK120 - Atopic Dermatitis | Phase 2 | Terminated | Akesobio Australia Pty Ltd | 79 | 2021-09-30 | 2025-02-26 |
| A Study of AK119 (Anti-CD73 Antibody), a Treatment for COVID-19, in Healthy Subjects AK119, Placebo - Coronavirus Disease 2019 (COVID-19) | Phase 1 | Completed | Akesobio Australia Pty Ltd | 29 | 2020-09-28 | 2025-02-28 |
| A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody in Subjects With Recurrent/Metastatic Cervical Cancer AK104 - Recurrent Cervical Cancer, Metastatic Cervical Cancer | Phase 2 | Completed | Akeso | 30 | 2020-07-15 | 2025-02-28 |
| A Study of AK120 (IL-4Rα) in Healthy Subjects and Subjects With Moderate- to- Severe Atopic Dermatitis AK120 or placebo- Part 1- Cohort 1, AK120 or placebo- Part 1- Cohort 2, AK120 or placebo- Part 1- Cohort 3 - Atopic Dermatitis | Phase 1 | Completed | Akesobio Australia Pty Ltd | 80 | 2020-06-15 | 2022-08-17 |
| A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK117 as Monotherapy or in Combination With AK104 AK117, AK117+AK104 - Neoplasms Malignant | Phase 1 | Completed | Akesobio Australia Pty Ltd | 38 | 2020-04-23 | 2024-08-21 |
| A Study of AK112, a PD-1/VEGF Bispecific Antibody, for Advanced Solid Tumors AK112 - Neoplasms Malignant | Phase 1 | Completed | Akesobio Australia Pty Ltd | 80 | 2019-09-20 | 2025-02-28 |
| A Study of AK111 in Healthy Subjects AK111 or Placebo - Psoriasis | Phase 1 | Completed | Akesobio Australia Pty Ltd | 68 | 2018-08-14 | 2025-02-28 |
| Study of the Safety, Pharmacokinetics, and Antitumor Activity of AK105 in Subjects With Advanced Solid Tumors AK-105 - Advanced Cancer | Phase 1 | Completed | Akesobio Australia Pty Ltd | 99 | 2018-01-02 | 2025-02-28 |
| Study of the Safety, Pharmacokinetics, and Antitumor Activity of AK104 in Subjects With Advanced Solid Tumors AK-104 - Advanced Cancer | Phase 1 | Completed | Akesobio Australia Pty Ltd | 119 | 2017-10-03 | 2025-02-28 |
Dermatitis, Atopic (2) · Neoplasms (2) · COVID-19 (1) · Colorectal Neoplasms (1) · Psoriasis (1) · Uterine Cervical Neoplasms (1)
Australia (8) · New Zealand (5) · United States (3)
Leslie Randall, MD (1) · Saurav Haldar, MD (1)
PMID 34473343, PMID 35165764, PMID 35833116, PMID 37668898, PMID 37852261, PMID 38280003, PMID 38642937